ACE2 and COVID-19: Experimental analysis showed that SARS-CoV-2, the etiologic agent of COVID-19, uses angiotensin-converting enzyme 2 (ACE2), which is primarily expressed in a small subset of cells in the lung called type 2 alveolar cells, as a cell receptor to gain entry to the cell [47].